Jim,Financial advisors often coach clients to diversify their portfolios, recommending they assign a certain percentage of assets to international or global funds to hedge against potential U.S. market declines. That’s the message delivered in an article from Reuters. It quotes IMS Health as seeing 12% to 14% pharmaceutical growth next near in Brazil, China, India, Mexico, Russia, South Korea, and Turkey. Emerging market growth is also predicted in the “2010 Forecast” to be published in the December issues of Healthcare Packaging and Packaging World magazines. The Reuters article reveals growth in emerging markets for companies including Pfizer, Novartis, GlaxoSmithKline Plc, Sanofi-Aventis, Novo Nordisk, and AstraZeneca Plc. Keep in mind that it’s important to develop a strategic approach to emerging markets, as long-term investments may be necessary to gain a satisfactory return on investment.
Global investment could yield a handsome return
Emerging markets could offset declining domestic income for U.S. pharmaceutical firms.
Nov 12th, 2009